EF Hutton Maintains Buy on UroGen Pharma, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for UroGen Pharma (NASDAQ:URGN) and maintained a price target of $25.
October 16, 2024 | 5:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for UroGen Pharma and maintained a price target of $25, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $25 price target by EF Hutton suggests positive sentiment and confidence in UroGen Pharma's future performance. This could lead to increased investor interest and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100